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Title: Interventions for Neurocognitive Dysfunction  
 
Abstract  
 
Purpose of review: To evaluate current barriers to HIV cure strategies and interventions for 
neurocognitive dysfunction with a particular focus on recent advancements over the last three years.  
Recent findings: Optimal anti-retroviral therapy (ART) poses challenges to minimise neurotoxicity, 
whilst ensuring blood brain barrier penetration and minimising the risk of cerebrovascular disease. 
CSF biomarkers, BCL11B and neurofilament light chain may be implicated with a neuroinflammatory 
cascade leading to cognitive impairment. Diagnostic imaging with diffusion tensor imaging as well as 
resting-state fMRI show promise in future diagnosis and monitoring of HAND. 
Summary: The introduction of ART has resulted in a dramatic decline in HIV-associated dementia. 
Despite this reduction, milder forms of HIV-associated neurocognitive disorder (HAND) are still 
prevalent and are clinically significant. The central nervous system (CNS) has been recognised as a 
probable reservoir and sanctuary for HIV, representing a significant barrier to management 
interventions. 
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Introduction 
 
The number of people worldwide living with HIV is over 35 million (WHO 2015). HIV has 
devastating effects on the immune system, resulting in acquired immunodeficiency syndrome (AIDS). 
It also contributes to a range of neurocognitive dysfunctions, collectively referred to as HIV-associated 
neurocognitive disorder (HAND) [1]. HAND incorporates a spectrum of cognitive impairment 
(categorised by the Frascati criteria) ranging from asymptomatic neurocognitive impairment (ANI) 
and mild neurocognitive disorder (MND) to HIV-associated dementia (HAD). Manifestations of 
HAND include impaired attention, memory, executive function, information processing speed and 
decision-making. Both ANI and MND are characterised by impaired cognition in two or more areas on 
neuropsychological testing, but while patients with MND have mild interference with functioning, 
patients with ANI are clinically asymptomatic. Alternatively, HAD is defined by marked cognitive 
impairment significantly affecting daily functioning [2].  
 
The largest study to examine cognitive impairment in HIV is the Central Nervous System (CNS) HIV 
Antiretroviral Therapy Effects Research (CHARTER) cross sectional cohort study which found 52% 
(814/1555) of HIV positive patients suffered cognitive impairment [3]. The prevalence of HAD has 
declined significantly since the introduction of anti-retroviral therapy (ART) in the 1990s [3, 4]. 
However, less severe forms of HAND (ANI and MND) are still prominent with estimates ranging 20-
50% [3, 5, 6]. Despite being asymptomatic, ANI is associated with increased risk of symptomatic 
decline (when compared to patients without neurocognitive impairment) [7], poorer quality of life and 
higher mortality [4] and is therefore important to address.  
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Existence of HIV Reservoirs: is the Central Nervous System Reservoir Real and is it Significant? 
 
Despite suppression of viral replication in the plasma, replication of HIV persists in multiple 
reservoirs throughout the body including resting memory CD4 T cells in the blood, lymph nodes, gut 
associated lymphoid tissue, genital tract, bone marrow, lungs, kidneys and most likely, the CNS [8]. 
The majority of research effort to date has been focused towards the largest HIV reservoir located 
within the CD4 T cells. The CNS reservoir however, is less well studied. Debate in the literature exists 
regarding the presence of the CNS reservoir and indeed its importance in HIV cure strategies. 
 
Formation of the CNS reservoir is believed to occur early during the course of infection. HIV enters 
the CNS by means of peripherally infected leukocytes (mainly monocytes), entering the Cerebral 
Spinal Fluid (CSF) as early as 2 weeks [9]. These monocytes and probably other cells act as “Trojan 
horses”, facilitating entry of HIV into the CSF [10]. Once in the CSF, infection of neighbouring cells 
(predominately perivascular macrophages and microglial cells) occurs via direct contact with 
monocytes. Neuropathological studies of the brain suggest that infection of these cells is highest 
around the perivascular areas [11].  
 
Blankson et al defined five specific characteristics that cells must meet in order to be considered 
biologically significant reservoirs of HIV-1. The cells must [1] contain integrated provirus, capable of 
replication, [2] be long-lived, allowing the virus to escape immune processes, [3] be significant in 
number, [4] require mechanisms to suppress the replication of HIV-1 and establish dormant infection, 
and finally [5] have the potential to be activated to produce new viral particles [12]. A review of the 
literature by Gray et al in 2014 established that the CNS fulfils most of these criteria to be considered 
as a reservoir [13]. 
 
Integrated HIV-1 provirus has been found in perivascular macrophages, microglia and astrocytes using 
fluorescence in-situ hybridisation and laser capture microdissection coupled with PCR [14, 15]. These 
cells are long-lived with half lives ranging from three months in macrophages [16], months to years in 
astrocytes [17] and years to lifetime in microglia [18]. The frequency of CNS cell infection has been 
demonstrated in several studies [15, 19]. Research by Eden et al found that up to 10% of patients with 
known HIV infection and undetectable HIV RNA plasma levels had raised HIV RNA in the CSF [20]. 
Gray et al have also established that HIV-1 within the CNS possess unique long terminal repeat 
sequences which allow the virus to remain dormant [21]. In-vitro studies have shown that astrocytes 
can be induced with interferon gamma, granulocyte macrophage colony stimulating factor and TNF 
alpha to artificially produce viral particles [22, 23]. What remains to be discovered is whether the 
integrated virus is capable of replication and whether or not the virus can be reactivated in vivo [24]. 
Finally, research by Gama et al has recently showed that the CNS harbors latent Simian 
Immunodeficiency Virus in macaques after lengthy ART suppression, further implicating the brain as 
a potential viral reservoir [25]. 
 
 
The Role of Astrocytes in the CNS HIV Reservoir 
 
The understanding of the role of astrocytes in HIV reservoirs is evolving. While astrocytes appear to 
be less involved with viral replication than perivascular macrophages and microglial cells, recent 
studies have shown that up to 19% of astrocytes can be infected in HAD, therefore representing a 
potentially significant viral reservoir [19]. Churchill et al found that astrocytes were more frequently 
 3 
infected with HIV in HAD and this was associated with the severity of HAND [19]. More recent 
research by Eugenin et al suggests that infected astrocytes may disturb the blood brain barrier (BBB) 
by triggering endothelial apoptosis [26]. A follow-up report from their research proposed that this 
astrocyte related disruption of the BBB may contribute to the formation of the CNS viral reservoir 
[27].  
 
 
Identifying the Central Nervous System Reservoir: Biomarkers 
 
The detection of biomarkers in the CNS is essential to evaluate the extent of the viral reservoir for 
HIV treatment monitoring. To date, no such markers have been validated. Researchers have proposed 
different CSF biomarkers including neurofilament light chain, neopterin and newer markers such as 
BCL11B. Neurofilament light chain (NFL) is one of the main components of the neuronal 
cytoskeleton and its CSF concentration is a sensitive marker of neuronal injury [28]. NFL CSF levels 
increase significantly in patients with HIV dementia and decrease with the commencement of ART. 
There is an approximate 42% reduction after 15 weeks of ART in some patients with elevated baseline 
CSF NFL levels [29]. CSF neopterin, a marker of CNS immune activation, is raised in nearly all 
patients with HAND on ART and in some patients without HAND. Its use as a biomarker is based on 
the concept that HIV in the CNS is not fully latent but instead shows periodic activity of replication 
with CNS damage, which may be subclinical. With cART CSF neopterin typically falls over several 
months, however often remains mildly elevated. BCL11B is a transcription factor which inhibits 
transcription of HIV-1. Desplats et al have found increased levels of BCL11B in patients with latent 
HIV infection in the CNS, defined as cases displaying proviral DNA in the brain with no productive 
infection. It has been proposed that BCL11B may trigger a neuroinflammatory cascade leading to 
cognitive impairment. BCL11B may represent an important potential biomarker of latent disease, 
although it usefulness in monitoring response to ART is not well understood [30]. The sample size of 
this study was small and larger studies are required to further assess the potential of BCL11B. The 
number of studies assessing CNS reservoir biomarkers is limited and it is therefore difficult to monitor 
disease activity in the CNS. Furthermore, CNS disease has been shown to occur in the absence of CSF 
viral load by current techniques [30], creating another hurdle to finding an ideal biomarker of the CNS 
reservoir.  
 
 
Antiretroviral Strategies to Treat HAND: Penetrating the Blood Brain Barrier 
 
The CNS reservoir poses a number of challenges with regards to HAND treatment strategies as there 
is good evidence that it is a sanctuary site. Firstly, can drugs commonly used to treat HIV (ARV) 
penetrate the BBB? Can drug treatments adequately target HIV infected cells? Is the CNS immune 
system then able to clear the virus?  
 
The BBB is a dynamic interface between the CNS and blood, formed by tight junctions between 
capillary endothelial cells which regulate the transport of molecules and cells. Increasing evidence 
suggests that ARVs differ in their ability to cross the BBB (as measured by their CSF concentrations). 
The ability of ARVs to penetrate the CNS depends on multiple favourable factors including low 
molecular weight, high lipid solubility, low degree of ionization, high affinity for transmembrane 
receptors and low protein binding [31]. To consolidate these characteristics, a CNS penetration 
effectiveness (CPE) score was introduced by Letendre et al [32].  
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ARVs with greater CNS penetration have been associated with reduced rates of HAND in some trials. 
Studies have also suggested that regimens with higher CPE scores are associated with a higher chance 
of undetectable CSF HIV RNA [32, 33]. Consequently, it has been suggested that ARVs with high 
penetration be selected for use in patients with HAND. Other trials however present conflicting data. 
A randomised controlled trial by Ellis et al showed no significant difference in neurocognitive 
outcomes when comparing treatment with ART with an expected high BBB penetration versus low 
BBB penetration [34]. This study however had significant limitations including a short lead in time  
(of 8 weeks) for ARV stability prior to study entry, high drop-out rate, early termination of the study 
and a higher proportion of patients in the optimised CPE group with comorbidities possibly 
contributing to cognitive dysfunction including Hepatitis C. Further, no measure of the BBB was 
incorporated into the trial: it could be argued that participants with an impaired BBB from HIV may 
not require ARVs with good penetration.   
 
Additionally, various studies have shown conflicting results as to whether or not HIV CSF levels 
correlate with changes in cognitive function [35]. Although often used as a surrogate marker of brain 
activity, CSF concentrations do not necessarily reflect those of brain tissue. Further criticisms of the 
CPE rank are that it does not take into account other important properties of ARV therapy including 
potential toxicity (both systemic, for example cardiovascular from Abacavir, and brain), 
compartmentalised resistance in the CNS and the possibility of pre-existing BBB impairment in some 
patients facilitating CNS entry of otherwise poorly penetrating ARVs. Furthermore, despite adequate 
concentrations in the CNS, some ARTs including the NRTIs zidovudine, lamivudine and stavudine, 
have demonstrated insufficient inhibitory activity in astrocytes, a potentially significant source of 
HIV-1 [36].  
 
Of the ART drug classes, non-nucleoside reverse transcriptase inhibitors (NNRTIs) generally score 
most favourably in terms of BBB penetration [37]. However, when taking into consideration the 
toxicity profiles of drugs, the NRTIs (including zidovudine, abacavir, lamivudine and emtricitabine) 
are preferred [38]. Protease inhibitors are poor penetrators of the BBB [39] due to their high protein 
binding and large molecular size. They are however potent with a high genetic barrier to resistance and 
thus present a possible future target, for example with nanoparticles. Dolutegravir, a once daily novel 
integrase inhibitor achieves acceptable therapeutic CSF concentrations, with BBB transport governed 
mainly by passive diffusion. It demonstrates a high CPE score of 4 and is considered favourable for 
treatment of HAND [40]. Maraviroc, a chemokine receptor type 5 (CCR5) entry inhibitor has also 
recently been shown to improve global neurocognitive functioning in virally suppressed men with 
HAND [41]. Maraviroc has shown good antiretroviral efficacy in cells including those of 
monocyte/macrophage lineage and good CNS penetration and demonstrates anti-inflammatory 
properties. It has been recently supported as part of intensification regimes to treat HAND [41]. 
 
 
Clearing Targeted Cells: is the Central Nervous System Immune System Capable?  
 
The CNS immune system is different to the rest of the body due its relative protection provided by the 
BBB. Immune recovery can paradoxically cause severe neurological disease. ART can indirectly 
cause neurotoxicity through immune reconstitution inflammatory syndrome (IRIS), caused by 
excessive response of the immune system to exposed antigens. Risk factors for developing IRIS 
include a very low CD4 count in addition to opportunistic infection (particularly JC virus, 
Cryptococcus and Mycobacterium Tuberculosis). HIV treatments therefore will likely require 
modulation of the CNS immune system [24].  
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There are two types of IRIS; the first type “unmasked” occurs in the context of an existing 
opportunistic infection and “paradoxic” where reactivation occurs without a previously diagnosed 
opportunistic pathogen [42]. The initiation of ART generates a prompt CNS immunological response 
to the pathogen, often associated with a significant inflammatory response. This is mediated by a pro-
inflammatory cytokine cascade, including (interleukin [IL]-6, IL-12, TNF-α) which are elevated in the 
CSF [43]. It is via this accelerated neuroinflammatory mechanism, including BBB breakdown, where 
IRIS is believed to be implicated in the cognitive and behavioural changes seen at least in some 
patients with HAND [42, 44]. Although rare, approximately 1% of patients commencing ART may 
develop CNS-IRIS. The clinical consequences can be devastating [45].  
 
The timing of ART commencement in the context of opportunistic infection is controversial due to the 
potential risk of IRIS. However, there is increasing support for the early introduction of ART in the 
hope of reducing the risk of AIDS-related morbidity and mortality via earlier immunologic recovery 
resulting in a faster clearance of the opportunistic infection [46, 47]. An exception to the above 
recommendation is Mycobacterium Tuberculosis infection in patients with a CD4 cell count below 
100 cells/microL as well as Toxoplasmosis and cryptococcal meningitis, where ART delay by two 
weeks for Tuberculosis and Toxoplasmosis, and five weeks for Cryptococcus is recommended [48]. 
This strategy is considered to minimise risk of IRIS, other opportunistic infections and death [49, 50]. 
The use of corticosteroids in patients at risk of encephalitis, cerebral oedema and herniation is 
controversial. There is a lack of controlled trials and hence for the majority of patients, a conservative 
management option is preferred with close observation [51, 52]. IRIS mediated BBB inflammation 
may cause obstruction of CSF outflow leading to intracranial hypertension [53].  
 
Progressive Multifocal Leukoencephalopathy (PML), caused by the JC virus, results in progressive 
demyelination of the CNS and is deleterious in potentiating cognitive impairment in HIV patients [54]. 
There are no proven efficacious treatments aside from ART and hence early treatment is 
recommended. In the setting of IRIS developing upon initiating ART, steroids may be required until 
memory T cell recovery is sufficient to arrest the JC virus [55]. Although evidence is lacking, early 
use of steroids may be beneficial in PML associated IRIS [55]. Ultimately, the ideal means of 
preventing IRIS is by “prophylactically” treating identified but subclinical or minimally clinical 
opportunistic infections with appropriate antimicrobial therapy (eg, Tuberculosis, Hepatitis B Virus, 
Pneumocystis and Cryptococcosis) for several months prior to initiation of ART [54, 56]. Patients who 
are receiving steroids for lengthy periods of time for IRIS should also receive prophylaxis for 
pneumocystis pneumonia and fungal infections, and for tuberculosis in endemic regions [42]. 
 
 
Neuroprotective Agents 
 
Several drugs have been trialled as adjunctive therapy in an attempt to reduce the inflammatory 
response and its consequence that persists despite suppressive ART. Agents trialled include N-methyl-
D-aspartate agonists, calcium channel blockers and antioxidants, which have shown minimal to no 
effect. Selegiline (a monoamine oxidase B inhibitor) is thought to provide neuroprotection by 
decreasing oxygen free radicals and increasing the production of neurotrophic factors. Previous studies 
with selegiline showed improvements in verbal memory and motor performance [57] however more 
recent studies have found no benefit [58].  
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Minocycline is believed to have CNS protective effects through a number of mechanisms including 
inhibition of apoptosis, the production of nitric oxide and subsequent oxygen free radicals. However, 
trials have not shown differences in markers of oxidative stress [59]. Memantine, an NMDA 
antagonist, has also unfortunately shown no improvement in cognitive function in a 48-week follow 
up study [60]. Small trials using nimodipine suggested some benefit; however, these results were 
inconclusive [61]. Unfortunately, no large RCTs have been performed and consequently no specific 
therapies with the exclusion of ART have been recommended for the routine treatment of HAND [4].  
 
 
ART neurotoxicity 
 
The significant decrease in HAD since the introduction of ART has raised little doubt that ART has 
been beneficial in reducing the more severe forms of HAND. However, the suggestion of poorer 
cognitive outcomes in some studies of high CPE regimens has prompted concerns of ART 
neurotoxicity [62]. There has been a relatively small focus on the potential neurotoxicity of ART to 
date.  
 
Increasing evidence suggests that ART causes toxicity to neurons via depletion of mitochondrial 
function and production of reactive oxygen species. This notion has been supported by a small autopsy 
study in which HIV infected individuals with HAND were more likely to display evidence of 
depletion of mitochondrial DNA in the frontal cortex with subsequent oxidative damage [63]. 
Furthermore, chronic administration of NRTIs in mice studies has shown to decrease the 
mitochondrial DNA in neurons of the frontal cortex [64].  
 
Data regarding neurotoxicity of specific first line ART agents are emerging. Of particular note is the 
toxicity associated with efavirenz, one of the most commonly prescribed agents. Early toxicity has 
been well described [65]. Additionally, long-term use has recently been associated with reduced 
cognitive function [66]. Antiretroviral switch studies have also shown improvement in general CNS 
symptoms when efavirenz is replaced with an alternative drug [67, 68]. Most other evidence regarding 
first line agents has come from case reports or series (see Table 1). 
 
 
Neuroimaging and HAND 
 
Several novel non-invasive magnetic resonance imaging (MRI) techniques have recently been 
evaluated. These extend beyond older findings on MRI T2 weighted sequences of generalised cerebral 
atrophy and white matter hyperintensities. They include more extensive MR spectroscopy (MRS), 
diffusion tensor imaging (DTI) and functional MRI (fMRI) with the more recent resting-state fMRI 
(RS-fMRI). Some of these imaging techniques may reflect early HIV subcortical changes over several 
months.  
 
MRS detects signal amplitude of specific cerebral metabolites within defined volumes of the brain. 
Frequently assessed metabolites include N-acetyl aspartate (a neuronal marker), choline (marker of 
cellular proliferation and inflammatory response), creatine (brain energy metabolism), myoinsitol (a 
putative marker of gliosis) and glutamine (measures neurotoxicity due to excess NMDA receptor 
activation). MRS studies of HAND have found decreased N-acetyl aspartate and raised choline and 
myoinositol levels. These changes have been found predominantly in the frontal white matter and 
basal ganglia [69]. More recent MRS studies have emphasised the importance of cardiovascular risk 
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factors and duration of HIV infection as independent factors for neuronal injury and inflammation in 
HAND. Cysique et al found that cardiovascular disease risk factors were associated with lower N-
acetyl aspartate in the posterior cingulate cortex and the caudate. Also noted was that an increased 
duration of HIV infection was associated with lower caudate N-acetyl aspartate. Greater CNS 
penetration of cART was associated with lower myo-inositol levels in the posterior cingulated cortex 
[70].  
 
DTI provides information about the movement of water molecules along fibre tracts. Recent studies 
have found DTI to be superior to conventional MRI in detecting white matter abnormalities in HAND 
[71, 72]. DTI may also be able to predict the severity of HAND [73-75]. Abnormalities in DTI have 
also shown to be reversible following ART, with improvement in the mean, axial and radial diffusivity 
of the corpus callosum and centrum semiovale of 21 patients over a six month period. These 
findings further support a potential future role of DTI in the diagnosis and monitoring of HAND [76].  
 
Functional MRI has shown to be sensitive in detecting mild cognitive abnormalities [77]. Recent 
research has found decreased blood flow and volume in patients with HAND, correlating with the 
severity of disease [78]. The more recent technique, RS-fMRI, measures low frequency fluctuations in 
the blood oxygenation level dependent signal at resting state (as opposed to task driven changes) to 
explore the functional architecture of the brain. RS-fMRI has identified various spatially distinct but 
functionally related areas of the brain. A recent cross-sectional study by Ann et al found significant 
differences in the fMRI patterns of HIV patients with HAND compared to HIV patients without 
HAND. Specifically, these changes were identified between the precuneus and prefrontal cortex [79]. 
The study however was limited by its small sample size and use of only male participants. Further 
studies are required to evaluate the potential role of RS-fMRI in HAND.  
 
 
Cerebrovascular Disease 
 
Since the introduction of ART there has been a significant reduction in HAD but not in the milder 
forms of HAND. This apparent therapeutic paradox has prompted investigation into other potential 
underlying causes. Recent research has looked towards vascular disease as a possible explanation. 
Specific ART regimens have been found to increase the risk of cerebrovascular disease (CVD) both 
directly, and indirectly, through increasing CVD risk factors including diabetes, hypertension and 
hyperlipidaemia [80-82]. This risk is particularly increased in those treated for long periods [83, 84]. 
In HIV un-infected patients, MRI detected white matter hyperintensities are believed to reflect 
ischaemia and have been associated with cognitive impairment (85). A recent study by Su et al found 
that periventricular MRI white matter hyperintensities were more extensive in HIV-infected men 
compared to un-infected controls and the extent of white matter hyperintensities correlated with the 
degree of cognitive impairment [86]. These findings are consistent with other research of HAND in 
the ART era [87] and provide support for the optimisation of cardiovascular risk factors in HIV 
infected patients. The conclusions of Su et al however were made through inference that white matter 
hyperintensities accurately reflect the burden of CVD. Further studies are warranted to further 
elucidate the role of CVD in HAND.  
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Future Directions 
 
A major barrier to HAND cure is the persistence of latently infected cells within the CNS. Recent 
studies have focused attention on latency reversing agents (LRAs) including histone deacetylase 
inhibitors, which aim to eliminate the obstacle of latency by stimulating transcription of dormant cells. 
The long terminal repeat sequences of CNS virus are believed to contain specific mutations, which 
allow the virus to remain latent. This has opened the door to potential targeted therapies [21]. 
However, eradication through a “shock and kill” strategy has the potential to induce robust 
inflammation with consequent brain damage [11]. Future studies will need to employ other techniques. 
 
In recent years, attention has been directed towards nanotechnology, including nanoparticles, as a 
technique to deliver ARVs across the BBB. Nanoparticles offer a number of desirable properties 
including versatility, small controllable size, large surface area to volume ratio and hydrophobicity 
[88]. Nanoparticles may ameliorate some of the limitations of cART, through improved toxicity 
profiles, selective drug delivery, increased drug stability and optimised drug distribution [89]. 
Although many novel nanotherapeutic techniques have been proposed, very few have reached clinical 
trials and it will likely take some time before the full potential of nanotechnology in HIV is realised.  
 
 
Conclusion 
 
This review has highlighted current barriers to HIV cure strategies and interventions for 
neurocognitive dysfunction. Recent studies continue to provide an improved understanding of the 
complex interaction of the CNS as a viral reservoir and its implications in HIV eradication. 
Developments in diagnostic imaging with diffusion tensor imaging as well as resting-state fMRI show 
promise in future diagnosis and monitoring of HAND. Improved HIV disease control due to cART has 
rendered neurocognitive management with a promising yet challenging outlook, balancing the effects 
of ART related neurotoxicity, optimising BBB penetration and CNS activity as well as managing the 
evolving risk of cerebrovascular disease. Future research in HAND is advancing with the development 
of LRAs as well as potential nanotechnology, improving CNS ART delivery. 
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Table 1: Neurotoxicity of Individual Anti-Retroviral Therapy 
Drug 
class 
Drug name CPE 
score 
CNS adverse effects 
NNRTIs Efavirenz 3 Neuropsychiatric symptoms including hallucinations, mood 
changes and delusions. Neurocognitive impairment [65] 
Rilpivirine 3 No reports to date 
Nevirapine 4 Behavioural and mood changes. Vivid dreams [90] 
Etravirine 2 Headache. Also associated with peripheral neuropathy [91] 
NRTIs Tenofovir 1 Neuropsychiatric symptoms [92] 
Abacavir 3 Neuropsychiatric symptoms, headache [93] 
Emtricitabine 3 Neuropsychiatric symptoms, headache [94] 
Lamivudine 2 No reports to date 
 Zidovudine 4 Headache, mood disturbance, dizziness [95] 
Protease 
inhibitors 
(with 
ritonavir) 
Darunavir 3 Headache [96] 
Indinavir 3 Headache, insomnia, dizziness, mood disturbance [96] 
Atazanavir 2 Headache and mood disturbance [97] 
Integrase 
inhibitors 
Raltegravir 3 Headache and neuropsychiatric symptoms including 
psychosis, nightmares, insomnia [98] 
Dolutegravir 4 Altered mood and insomnia [99] 
Elvitegravir 2 No reports to date 
Entry 
inhibitors 
Maraviroc 3 No reports to date 
   
Fusion 
inhibitors 
Enfuviritide 1 Headache, dizziness, taste disturbance. Also associated with 
peripheral neuropathy [100] 
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